3 ms·

So for instance, take a look at this study on the cost/benefit evaluation of patent extensions in the pharma industry: https://www.ncbi.nlm.nih.gov/pmc/article

by skohan 7y ago

So for instance, take a look at this study on the cost/benefit evaluation of patent extensions in the pharma industry: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672218/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672218/ What they found is that the strategies used by drug companies to "evergreen" their patented drugs resulted in massive unnecessary expenditures with negligible differences in outcomes.

refurb 7y ago
Yeah, but that article suggests the problem lies with the hospital, not the drug company. The hospital is choosing to use these marginally better drugs over the cheaper generics. And I take issue with their claim that pregabalin is an evergreen strategy for gabapentin. Those are two very different drugs.